CFAP65: Target/Biomarker Introduction, products summarized (antibody/ADC/bispecific/antigen/ORF vector/VLP) and disease/indication/condition/MOA for drug discovery and IVD

It's the GeneMedi's summary page for Target/Biomarker Introduction of CFAP65. The page also collects GeneMedi's different modalities and formats products for CFAP65 in therapeutics/drug discovery and IVD diagnostics, which is including antibody, ADC, bispecific, antigen, ORF vector, VLP, etc. With GeneMedi's target-insight database-GM ITD database, the CFAP65 target is also connected to human indications/diseases/conditions/MOA.

Target sublocation: Transmembrane Protein.

The protein encoded by this gene has putative coiled-coil domains and may be a transmembrane protein. The chicken ortholog of this gene is involved in the Rose-comb mutation, which is a large chromosome inversion, resulting in altered comb morphology and defects in sperm motility. [provided by RefSeq, Aug 2016]

Target IDGM-MP2602
Target NameCFAP65
Gene ID255101,241116,301521,701296,488532,101099894,107131175,100058974
Gene Symbol and SynonymsA230051F10,B230363K08Rik,CCDC108,CFAP65,SPGF40
Uniprot AccessionQ6ZU64
Uniprot Entry NameCFA65_HUMAN
Protein Sub-locationTransmembrane Protein
Category
DiseaseN/A
Gene EnsemblENSG00000181378
Target ClassificationN/A


Pre-made anti-CFAP65 inhibitory monoclonal antibody(mab, blocking antibody inhibitor)-benchmark antibody for drug discovery and mechanism of action (MOA) research

Pre-made anti-CFAP65 benchmark inhibitory monoclonal antibody(mab, blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic). The anti-CFAP65 mab is expressed and produced by mammalian cell line as a benchmark reference therapeutic antibody for biological drug discovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Antibody NameSpeciesFormatClassified by tagDetail
Anti-CFAP65 monoclonal antibodyHuman, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, EquinemabFACS/Biofunctional AntibodyDetail



Multi-species CFA65/ CFAP65/ CCDC108 VLP (virus-like particle) for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis

Genemedi produces Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine CFAP65 VLP (virus-like particle) for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis.

Products NameSpeciesExpression PlatformDetail
CFAP65 VLP (virus-like particle)Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, EquineMammalian cellProducts Developing






GENEMEDI
Email: [email protected]   [email protected]
Telephone: +86-21-50478399   Fax: 86-21-50478399
Privacy Policy
<